Beyond PD-L1, other potential biomarkers, including gut microbiota, circulating tumor DNA (ctDNA), and tumor-infiltrating lymphocytes, have been investigated for their predictive value in HCC treatment (37). The gene discussed is CD274; the disease is hepatocellular carcinoma.